Glucose monitor helps manage alpelisib side effect in breast cancer
NCT ID NCT06083038
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 17 times
Summary
This study looked at how a continuous glucose monitor (CGM) could help track and manage high blood sugar in 8 adults with metastatic breast cancer starting the drug alpelisib. Participants wore a sensor that measured glucose every minute for at least 3 months. The goal was to understand when blood sugar peaks after taking alpelisib and to help prevent or manage this common side effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HealthPartners Cancer Research Center
Saint Louis Park, Minnesota, 55426, United States
Conditions
Explore the condition pages connected to this study.